Literature DB >> 27300744

Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?

Aldo G Carrizo1, Carlos A Morillo2,3.   

Abstract

Current guidelines include atrial fibrillation (AF) catheter ablation as part of the management strategy in patients that have failed at least one oral antiarrhythmic drug treatment course. However, growing evidence derived from both randomized and non-randomized studies demonstrate lower rates of AF recurrence and AF burden in patients with paroxysmal AF that are naïve to antiarrhythmic drug treatment. Furthermore, progression from paroxysmal AF to persistent AF appears to be delayed by early catheter ablation of AF. The current review addresses the question of the best timing for ablation in patients with paroxysmal AF and provides the rationale for offering AF ablation as first-line therapy based on the most updated evidence available.

Entities:  

Keywords:  Atrial fibrillation; Atrial remodeling; Catheter ablation; Paroxysmal

Mesh:

Substances:

Year:  2016        PMID: 27300744     DOI: 10.1007/s11886-016-0747-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  33 in total

1.  Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat.

Authors:  Jannie Ausma; Huub M W van der Velden; Marie-Hélène Lenders; Erwin P van Ankeren; Habo J Jongsma; Frans C S Ramaekers; Marcel Borgers; Maurits A Allessie
Journal:  Circulation       Date:  2003-04-07       Impact factor: 29.690

Review 2.  Ablation versus drugs: what is the best first-line therapy for paroxysmal atrial fibrillation? Antiarrhythmic drugs are outmoded and catheter ablation should be the first-line option for all patients with paroxysmal atrial fibrillation: pro.

Authors:  Pasquale Santangeli; Luigi Di Biase; Andrea Natale
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-08

3.  Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Andrea Natale; Douglas Packer; Allan Skanes; Federico Ambrogi; Elia Biganzoli
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-07

4.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

Authors:  Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale
Journal:  JAMA       Date:  2005-06-01       Impact factor: 56.272

5.  Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.

Authors:  Thomas Vanassche; Mandy N Lauw; John W Eikelboom; Jeff S Healey; Robert G Hart; Marco Alings; Alvaro Avezum; Rafael Díaz; Stefan H Hohnloser; Basil S Lewis; Olga Shestakovska; Jia Wang; Stuart J Connolly
Journal:  Eur Heart J       Date:  2014-09-03       Impact factor: 29.983

6.  Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center.

Authors:  Geoffrey Lee; Paul B Sparks; Joseph B Morton; Peter M Kistler; Jitendra K Vohra; Caroline Medi; Raphael Rosso; Andrew Teh; Karen Halloran; Jonathan M Kalman
Journal:  J Cardiovasc Electrophysiol       Date:  2010-08-19

7.  Current status of catheter ablation of atrial fibrillation in Japan: Summary of the 4th survey of the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF).

Authors:  Koichi Inoue; Yuji Murakawa; Akihiko Nogami; Morio Shoda; Shigeto Naito; Koichiro Kumagai; Yasushi Miyauchi; Teiichi Yamane; Norishige Morita; Ken Okumura
Journal:  J Cardiol       Date:  2015-09-19       Impact factor: 3.159

8.  Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes.

Authors:  T Jared Bunch; Heidi T May; Tami L Bair; David L Johnson; J Peter Weiss; Brian G Crandall; Jeffrey S Osborn; Jeffrey L Anderson; J Brent Muhlestein; Donald L Lappe; John D Day
Journal:  Heart Rhythm       Date:  2013-05-20       Impact factor: 6.343

9.  In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures.

Authors:  Abhishek Deshmukh; Nileshkumar J Patel; Sadip Pant; Neeraj Shah; Ankit Chothani; Kathan Mehta; Peeyush Grover; Vikas Singh; Srikanth Vallurupalli; Ghanshyambhai T Savani; Apurva Badheka; Tushar Tuliani; Kaustubh Dabhadkar; George Dibu; Y Madhu Reddy; Asif Sewani; Marcin Kowalski; Raul Mitrani; Hakan Paydak; Juan F Viles-Gonzalez
Journal:  Circulation       Date:  2013-09-23       Impact factor: 29.690

10.  First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs. cryoballoon pulmonary vein isolation.

Authors:  Florian Straube; Uwe Dorwarth; Sonia Ammar-Busch; Timo Peter; Georg Noelker; Thomas Massa; Malte Kuniss; Niels Christian Ewertsen; Kyoung Ryul Julian Chun; Juergen Tebbenjohanns; Roland Tilz; Karl Heinz Kuck; Taoufik Ouarrak; Jochen Senges; Ellen Hoffmann
Journal:  Europace       Date:  2015-10-25       Impact factor: 5.214

View more
  2 in total

1.  CVAR-Seg: An Automated Signal Segmentation Pipeline for Conduction Velocity and Amplitude Restitution.

Authors:  Mark Nothstein; Armin Luik; Amir Jadidi; Jorge Sánchez; Laura A Unger; Eike M Wülfers; Olaf Dössel; Gunnar Seemann; Claus Schmitt; Axel Loewe
Journal:  Front Physiol       Date:  2021-05-24       Impact factor: 4.566

2.  Left Atrial Stiffness: A Predictor of Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation - A Systematic Review and Meta-Analysis.

Authors:  Eduardo Thadeu de Oliveira Correia; Letícia Mara Dos Santos Barbetta; Othon Moura Pereira da Silva; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2019-03-07       Impact factor: 2.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.